Pandemic Flu Prep: An Interview With Novartis Vaccines Chief Andrin Oswald
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis recently produced its first batch of H1N1 vaccine, but winning approval for a cell-based vaccine could prove challenging in the U.S.